Jacob O Levitt MDVice Chairman, Program Director, and Associate Professor and Attending, Dermatlogy Department, The Mount Sinai Medical Center, New York, NY
Jacob Oren Levitt, M.D. is Vice Chairman, Program Director, and Associate Professor and Attending at The Mount Sinai Medical Center, New York, NY. He was Course Director of the second year medical student dermatology pathophysiology course at The Mount Sinai School of Medicine, New York, NY for ten years from his Chief Residency year at Mount Sinai in 2004 until 2014. In 2010, he became Residency Director of Dermatology. Clinical interests include autoimmune bullous disease, head lice, scabies, and medical education. Dr. Levitt did his dermatology residency at The Mount Sinai Medical Center, New York, NY, his internship at Sound Shore Medical Center, New Rochelle, NY, and medical school training at the Albert Einstein College of Medicine, Bronx, NY. He received a B.A. degree in Chemistry from Yale University. Dr. Levitt has competency in conversational Hebrew and Spanish, and some French and Japanese.
Dr. Levitt has over 60 publications, including 7 book chapters and one book. He has been a speaker at the American Academy of Dermatology on head lice and scabies and on procedural safety in dermatology. From 2004-2010, Dr. Levitt was a vice president of Taro Pharmaceuticals U.S.A., Inc., a company founded by his grandfather. Dr. Levitt holds one patent on a novel treatment for acne. He is past President of the Manhattan Metropolitan Dermatological Society (2011-2012) and past President of the New York Academy of Medicine Dermatology Section (2012-2013) and current Secretary for the New York State Society of Dermatology and Dermatologic Surgery (2013-2015). He is currently a member to the American Academy of Dermatology Scientific Assembly Committee (March 2015 – March 2020).
Recent Contributions to PracticeUpdate:
- Triggers, Clinical Manifestations, and Management of Pediatric Erythema Multiforme
- Pharmacy Costs of Specialty Medications for Plaque Psoriasis in the United States
- GP2015 Comparable With Etanercept Originator in Efficacy and Safety in Chronic Plaque-Type Psoriasis
- The State and Consequences of Dermatology Drug Prices in the United States
- Ivermectin Improves Quality of Life in People With Rosacea
- Sky High 6-Year Increase in Retail Prices of Prescription Dermatologic Drugs